ISIS Financial Facts
Total operating expenses: 41.74MTotal revenue: 43.36M
See Full Income Statement
Accrued liabilities: 17.76M
Total current liabilities: 70.3M
See Full Balance Sheet
Earnings History for Isis Pharmaceuticals, Inc. (ISIS)
|
Expand Research on ISIS
| Next EPS Date | 8/5/13 *Est. | EPS Growth Rate | +91.7% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | +33.7% | Revenue Growth Rate | +86.9% *Last Qtr. |
| Average % Move 1-Wk after EPS | +4.7% |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Estimize EPS/Revs | Gd. | % Since | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
2/28/11  |
 |
Q410 | -$0.14 | -$0.22 | +$0.08 | $26.4M | $22.55M | N/A / N/A | N/A | +129.9% | Details |
| 5/5/11 |
|
Q111 | -$0.20 | -$0.19 | -$0.01 | $21.1M | $25.69M | N/A / N/A | N/A | +139.2% | Details |
| 8/4/11 |
|
Q211 | -$0.18 | -$0.22 | +$0.04 | $24.8M | $23.98M | N/A / N/A | N/A | +180.8% | Details |
| 11/7/11 |
|
Q311 | -$0.27 | -$0.20 | -$0.07 | $20.7M | $25.33M | N/A / N/A | N/A | +151.3% | Details |
| 2/29/12 |
|
Q411 | -$0.20 | -$0.18 | -$0.02 | $32.4M | $30.3M | N/A / N/A | N/A | +141.7% | Details |
| 5/8/12 |
|
Q112 | -$0.24 | -$0.26 | +$0.02 | $23.2M | $22.72M | N/A / N/A | N/A | +158.2% | Details |
| 8/6/12 |
Q212 | -$0.01 | -$0.10 | +$0.09 | $47.3M | $40.06M | N/A / N/A | N/A | +72.3% | Details | |
| 11/6/12 |
Q312 | -$0.37 | -$0.26 | -$0.11 | $11.6M | $23.11M | N/A / N/A | N/A | +138.6% | Details |
